Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Opinion Article

Is There Any Role of IL-6 Inhibition in COVID-19?

Author(s): Rebecca Cannon and Satyajit Das*

Volume 2, Issue 7, 2021

Published on: 23 November, 2020

Article ID: e250621188252 Pages: 6

DOI: 10.2174/2666796701999201123102516

Price: $65

Abstract

An emergent coronavirus, now named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), was declared a pandemic on the 22nd March 2020. It has since caused unprecedented pressures on the healthcare systems worldwide, leading to over five million cases and over three hundred thousand deaths. This has resulted in a global struggle to fight this disease, without any known cure or any definite treatment and with no vaccine. This challenge is exemplified by many with COVID-19 (Coronavirus Disease 2019) rapidly deteriorating to critical illness, developing respiratory failure, multi-organ dysfunction or failure, and septic shock. This rapid deterioration is thought to be due to the activation of the cytokine storm.

The cytokine storm is characterised by mass cytokine and chemokine release, leading to widespread multi-organ damage. One of these such cytokines that plays a role in the cytokine storm is Interleukin (IL-) 6. Raised levels of IL-6 in many diseases have been observed to both correlate with disease severity and predict poor outcomes. Early studies began to show high levels of IL-6 in those with severe and critical COVID-19, and there is ongoing research into immune modulators to block IL-6, in the hope of halting disease progression and improving the chance of recovery. This article will explore the role that IL-6 plays in COVID-19 and whether an IL-6 blockade can prevent poor outcomes and reduce mortality.

Keywords: COVID-19, IL-6, tocilizumab, coronavirus, SARS-CoV-2, cytokine storm.

[1]
World Health Organization. Middle east respiratory syndrome coronavirus (MERS-CoV). Available from: https://www.who.int/emergencies/mers-cov/en/
[2]
World Health Organization. cumulative number of reported probable cases of SARS. Available from: http://www10.who.int/csr/ sars/country/2003_05_23/en/
[3]
World Health Organization. Coronavirus Disease (COVID-19) pandemic. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
[4]
Duddu P. Coronavirus treatment: Vaccines/drugs in the pipeline for COVID-19. Available from: https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/
[5]
Sarzi-Puttini P, Giorgi V, Sirotti S, et al. COVID-19, cytokines and immunosuppression: What can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol 2020; 38(2): 337-42.
[PMID: 32202240]
[6]
Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: Interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 2020; 55(5): 105954.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105954] [PMID: 32234467]
[7]
Rabby I. Current drugs with potential for treatment of COVID-19: A literature review. J Pharm Pharm Sci 2020; 23(1): 58-64.
[http://dx.doi.org/10.18433/jpps31002] [PMID: 32251618]
[8]
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395(10223): 473-5.
[http://dx.doi.org/10.1016/S0140-6736(20)30317-2] [PMID: 32043983]
[9]
Randomised evaluation of COVID-19 therapy. Low-cost dexamethasone reduces death by up to one third in hospitalized patients with severe respiratory complications of COVID-19. Available from: https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19
[10]
WHO welcomes preliminary results about dexamethasone use in treating critically ill COVID-19 patients. Available from: https://www.who.int/news-room/detail/16-06-2020-who-welcomes-preliminary-results-about-dexamethasone-use-in-treating-critically-ill-covid-19-patients
[11]
2019. BMJ. Coronavirus disease 2019 (COVID-19). Available from: https://bestpractice.bmj.com/topics/en-gb/3000168/treatment-algorithm#patientGroup-0-1
[12]
National Institutes of Health. Coronavirus disease 2019 (covid-19) treatment guidelines. 2019. Available from: https://www.covid19treatmentguidelines.nih.gov/
[13]
European Medicines Agency. Treatments and vaccines for COVID-19. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines-covid-19
[14]
National institute for health and care excellence. COVId 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed covid-19. Available from: https://www.nice.org.uk/advice/es27/chapter/Key-messages
[15]
Cascella M, Rajnik M, Cuomo A, Dulebohn S, Napoli R. features, evaluation and treatment coronavirus (COVID-19). Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/
[16]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020; 395(10223): 507-13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[17]
Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014; 6(10): a016295.
[http://dx.doi.org/10.1101/cshperspect.a016295] [PMID: 25190079]
[18]
Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev 2012; 76(1): 16-32.
[http://dx.doi.org/10.1128/MMBR.05015-11] [PMID: 22390970]
[19]
Wang S, Le TQ, Kurihara N, et al. Influenza virus-cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza. J Infect Dis 2010; 202(7): 991-1001.
[http://dx.doi.org/10.1086/656044] [PMID: 20731583]
[20]
Okabayashi T, Kariwa H, Yokota S, et al. Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections. J Med Virol 2006; 78(4): 417-24.
[http://dx.doi.org/10.1002/jmv.20556] [PMID: 16482545]
[21]
Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020; 71(15): 762-8.
[http://dx.doi.org/10.1093/cid/ciaa248] [PMID: 32161940]
[22]
Borges ÁH, O’Connor JL, Phillips AN, et al. Factors associated with plasma IL-6 levels during HIV infection. J Infect Dis 2015; 212(4): 585-95.
[http://dx.doi.org/10.1093/infdis/jiv123] [PMID: 25722296]
[23]
Borges ÁH, O’Connor JL, Phillips AN, et al. Interleukin 6 is a stronger predictor of clinical events than high-sensitivity C-reactive protein or D-dimer during HIV infection. I. J Infect Dis 2016; 214(3): 408-16.
[http://dx.doi.org/10.1093/infdis/jiw173] [PMID: 27132283]
[24]
Damas P, Ledoux D, Nys M, et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992; 215(4): 356-62.
[http://dx.doi.org/10.1097/00000658-199204000-00009] [PMID: 1558416]
[25]
Srisangthong P, Wongsa A, Kittiworawitkul P, Wattanathum A. Early IL-6 response in sepsis is correlated with mortality and severity score. Crit Care 2013; 17(Suppl. 2): 34.
[http://dx.doi.org/10.1186/cc11972]
[26]
Thao PTN, Tra TT, Son NT, Wada K. Reduction in the IL-6 level at 24 h after admission to the intensive care unit is a survival predictor for Vietnamese patients with sepsis and septic shock: a prospective study. BMC Emerg Med 2018; 18(1): 39.
[http://dx.doi.org/10.1186/s12873-018-0191-4] [PMID: 30400775]
[27]
Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis. J Med Virol 2020; 92(11): 2283-5.
[http://dx.doi.org/10.1002/jmv.25948] [PMID: 32343429]
[28]
Herold T, Jurinovic V, Arnreich C, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol 2020; 146(1): 128-136.e4.
[http://dx.doi.org/10.1016/j.jaci.2020.05.008] [PMID: 32425269]
[29]
Rapid Review MOH-ACE. Should interleukin-6 inhibitors be used for COVID-19? Available from: https://www.moh.gov.sg/docs/librariesprovider5/clinical-evidence-summaries/il-6-inhibitors-in-covid-19-(24-march-2020).pdf
[30]
Clinical Trials. Anti-il6 Treatment of serious COVID-19 disease with threatening respiratory failure (TOCIVID). Available from: https://www.clinicaltrials.gov/ct2/show/NCT04322773
[31]
Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol 2011; 163(1): 29-43.
[http://dx.doi.org/10.1111/j.1476-5381.2010.01199.x] [PMID: 21198556]
[32]
Kellum JA, Venkataraman R, Powner D, Elder M, Hergenroeder G, Carter M. Feasibility study of cytokine removal by hemoadsorption in brain-dead humans. Crit Care Med 2008; 36(1): 268-72.
[http://dx.doi.org/10.1097/01.CCM.0000291646.34815.BB] [PMID: 18090355]
[33]
Honore PM, Hoste E, Molnár Z, et al. Cytokine removal in human septic shock: Where are we and where are we going? Ann Intensive Care 2019; 9(1): 56.
[http://dx.doi.org/10.1186/s13613-019-0530-y] [PMID: 31089920]
[34]
Perricone C, Triggianese P, Bartoloni E, et al. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun 2020; 111: 102468.
[http://dx.doi.org/10.1016/j.jaut.2020.102468] [PMID: 32317220]
[35]
Monteagudo LA, Boothby A, Gertner E. Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome. ACR Open Rheumatol 2020; 2(5): 276-82.
[http://dx.doi.org/10.1002/acr2.11135] [PMID: 32267081]
[36]
Clinical trials. anakinra for covid-19 respiratory symptoms (ANACONDA). Available from: https://clinicaltrials.gov/ct2/show/NCT04364009
[37]
Clinical trials.corimuno-ana: trial evaluating efficacy of anakinra in patients with covid-19 infection (corimuno-ana). Available from: https://clinicaltrials.gov/ct2/show/NCT04341584
[38]
Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 2020; 117(20): 10970-5.
[http://dx.doi.org/10.1073/pnas.2005615117] [PMID: 32350134]
[39]
Michot JM, Albiges L, Chaput N, et al. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol 2020; 31(7): 961-4.
[http://dx.doi.org/10.1016/j.annonc.2020.03.300] [PMID: 32247642]
[40]
Alattar R, Ibrahim TBH, Shaar SH, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol 2020; 92(10): 2042-9.
[http://dx.doi.org/10.1002/jmv.25964] [PMID: 32369191]
[41]
Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol 2020; 92(7): 814-8.
[http://dx.doi.org/10.1002/jmv.25801] [PMID: 32253759]
[42]
Lu CC, Chen MY, Lee WS, Chang YL. Potential therapeutic agents against COVID-19: What we know so far. J Chin Med Assoc 2020; 83(6): 534-6.
[http://dx.doi.org/10.1097/JCMA.0000000000000318] [PMID: 32243270]
[43]
Radbel J, Narayanan N, Bhatt PJ. Use of tocilizumab for COVID-19-induced cytokine release syndrome: a cautionary case report. Chest 2020; 158(1): e15-9.
[http://dx.doi.org/10.1016/j.chest.2020.04.024] [PMID: 32343968]
[44]
Roche. Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia. Available from: https://www.roche.com/investors/updates/inv-update-2020-07-29.html
[45]
Gov.UK. COVID-19 treatments could be fast-tracked through new national clinical trial initiative. Available from: https://www.gov.uk/government/news/covid-19-treatments-could-be-fast-tracked-through-new-national-clinical-trial-initiative
[46]
The World Health Organization. “Solidarity” clinical trial for COVID-19 treatments. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments

Rights & Permissions Print Cite
Article Metrics
11
2
1
© 2024 Bentham Science Publishers | Privacy Policy